Website Updates
2013
Interferon Free Combinations
Achillion:
Poised For Growth And Now Is The Time To Buy
What is notable
is that Achillion has 4 drugs in the mix; ACH-2684, 2928, 3102 and 1625. Each
of which are showing strong promise at various phase I and II trials, and can
either work independently or in combination in an oral fashion, not injections.
2013 Sofosbuvir (GS-7977)
The following two downloads are provided via NATAP's mailing list
Subscribe to the NATAP
HCV Mailing List by email: nataphcv-request@natap.org
*with a subject line of subscribe
Learn more here
Nucleotide Polymerase
Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
The
standard treatment for hepatitis C virus (HCV) infection is interferon,which is
administered subcutaneously and can have troublesome side effects.We evaluated
sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in
interferon-sparing and interferon-free regimens for the treatment of HCV
infection.
Download
Full Text Here
Exploratory Study of
Oral Combination Antiviral Therapy for Hepatitis C
There is a need
for interferon-free treatment regimens for hepatitis C virus (HCV) infection.
The goal of this study was to evaluate ABT-450, a potent HCV NS3 protease
inhibitor,
combined with low-dose ritonavir (ABT-450/r), in addition to
ABT-333, a nonnucleoside NS5B polymerase inhibitor, and ribavirin, for the
treatment of HCV infection
View PDF ---
nejmoa1208809.pdf
466K View
nejmoa1208809_appendix-1.pdf 115K View
nejmoa1208809_appendix.pdf 115K View
Chronic
Hepatitis C Infection: Treat Now or Wait?
2013-Hepatitis
C Full Text Articles
2013-HCV Abstract Corner
HCV
Advocate - Top News of 2012
A milestone—GS-7977
Outbreaks of HCV in Health Care Settings
First
National Helpline
DAA’s and Transplant Patients
and
more........
In The News
Microbiotix
Announces Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside
Polymerase Inhibitors
Revolutionary
techniques could help harness patients' own immune cells to
fight disease
No comments:
Post a Comment